296 related articles for article (PubMed ID: 18093685)
1. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
[TBL] [Abstract][Full Text] [Related]
2. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.
Vogel A; van Den Berg IE; Al-Dhalimy M; Groopman J; Ou CN; Ryabinina O; Iordanov MS; Finegold M; Grompe M
Hepatology; 2004 Feb; 39(2):433-43. PubMed ID: 14767996
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
4. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
5. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.
Marhenke S; Lamlé J; Buitrago-Molina LE; Cañón JM; Geffers R; Finegold M; Sporn M; Yamamoto M; Manns MP; Grompe M; Vogel A
Hepatology; 2008 Aug; 48(2):487-96. PubMed ID: 18666252
[TBL] [Abstract][Full Text] [Related]
6. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
7. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
8. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
Eggenhofer E; Doenecke A; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
J Gastroenterol Hepatol; 2010 May; 25(5):1002-8. PubMed ID: 20546455
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress.
Dieter MZ; Freshwater SL; Miller ML; Shertzer HG; Dalton TP; Nebert DW
Free Radic Biol Med; 2003 Aug; 35(4):351-67. PubMed ID: 12899938
[TBL] [Abstract][Full Text] [Related]
10. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.
Langlois C; Jorquera R; Orejuela D; Bergeron A; Finegold MJ; Rhead WJ; Tanguay RM
Mol Genet Metab; 2008 Mar; 93(3):306-13. PubMed ID: 18023223
[TBL] [Abstract][Full Text] [Related]
11. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
12. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1.
Tanguay RM; Angileri F; Vogel A
Adv Exp Med Biol; 2017; 959():49-64. PubMed ID: 28755183
[TBL] [Abstract][Full Text] [Related]
14. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine and its catabolites: from disease to cancer.
Tanguay RM; Jorquera R; Poudrier J; St-Louis M
Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
[TBL] [Abstract][Full Text] [Related]
17. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.
Overturf K; Al-Dhalimy M; Tanguay R; Brantly M; Ou CN; Finegold M; Grompe M
Nat Genet; 1996 Mar; 12(3):266-73. PubMed ID: 8589717
[TBL] [Abstract][Full Text] [Related]
18. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.
Grompe M; Lindstedt S; al-Dhalimy M; Kennaway NG; Papaconstantinou J; Torres-Ramos CA; Ou CN; Finegold M
Nat Genet; 1995 Aug; 10(4):453-60. PubMed ID: 7545495
[TBL] [Abstract][Full Text] [Related]
20. Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1.
Elgilani F; Mao SA; Glorioso JM; Yin M; Iankov ID; Singh A; Amiot B; Rinaldo P; Marler RJ; Ehman RL; Grompe M; Lillegard JB; Hickey RD; Nyberg SL
Am J Pathol; 2017 Jan; 187(1):33-41. PubMed ID: 27855279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]